A study to describe and evaluate patient characteristics and clinical outcomes in Subjects with diagnosed Non Small Lung Cell Cancer in Sweden, Norway and Denmark.
Study Type
OBSERVATIONAL
Enrollment
5,657
Overall survival based on Response Evaluation Criteria in Solid Tumors (RECIST)
Overall survival is defined as the time from start of treatment to the end of follow-up; Clinical outcomes will be assessed among NSCLC patients with advanced (stage IIIB and above) and earlier stage (stages I to IIIA) disease
Time frame: Approximately 2 years
Progression free survival based on Response Evaluation Criteria in Solid Tumors (RECIST)
Progression free survival is defined as the time from date of treatment start to either the first disease progression date or last known tumor assessment date or death; Clinical outcomes will be assessed among NSCLC patients with advanced (stage IIIB and above) and earlier stage (stages I to IIIA) disease
Time frame: Approximately 2 years
Time to progression based on Response Evaluation Criteria in Solid Tumors (RECIST)
Time to progression is defined as time from start of therapy until tumor progression; Clinical outcomes will be assessed among NSCLC patients with advanced (stage IIIB and above) and earlier stage (stages I to IIIA) disease
Time frame: Approximately 2 years
Disease control rate; defined as total number of patients whose Best Overall Response(BOR)= Complete Response(CR), Partial Response(PR) or Stable Disease(SD), divided by total number of patients
Clinical outcomes will be assessed among NSCLC patients with advanced (stage IIIB and above) and earlier stage (stages I to IIIA) disease; BOR: Best Overall Response, CR: Complete Response, PR: Partial Response, SD: Stable Disease
Time frame: Approximately 2 years
Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST)
Partial response is defined as a record of at least a 30% decrease in the sum of diameters of target lesions, from the baseline sum; Clinical outcomes will be assessed among NSCLC patients with advanced (stage IIIB and above) and earlier stage (stages I to IIIA) disease
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Approximately 2 years
Complete response based on Response Evaluation Criteria in Solid Tumors (RECIST)
Complete response is defined as a record of disappearance of all target lesions; Clinical outcomes will be assessed among NSCLC patients with advanced (stage IIIB and above) and earlier stage (stages I to IIIA) disease
Time frame: Approximately 2 years
Percent of patients with an adverse event (AE)
Patients with advanced stage (stage IIIB and above) disease; AEs are defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
Time frame: Approximately 2 years
Percent of patients with an adverse event (AE)
Patients with earlier stage (stages I to IIA) disease; AEs are defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
Time frame: Approximately 2 years
Body Mass Index (BMI) of NSCLC patients at diagnosis
Time frame: At baseline visit
Smoking habits of NSCLC patients at diagnosis
Time frame: At baseline visit
Age of NSCLC patients at diagnosis
Time frame: At baseline visit
NSCLC clinical subtype of NSCLC patients at diagnosis
Time frame: At baseline visit
Tumor node metastasis classification of NSCLC patients at diagnosis
Time frame: At baseline visit
Charlson Comorbidity index of NSCLC patients at diagnosis
Time frame: At baseline visit
Drug utilization after NSCLC diagnosis by line of therapy
Time frame: Approximately 2 years
Proportion of patients who receive surgery by stage at treatment
Time frame: Approximately 2 years
Proportion of patients who receive radiation by stage at treatment
Time frame: Approximately 2 years